Masthead Stars

First Nation Group Partners with Signifier® Medical Technologies

First Nation Group partners with pioneer in patient-friendly therapies for sleep disordered breathing, Signifier® Medical Technologies

First Nation Group, a full-service, stocking supplier serving the Department of Veteran Affairs and Department of Defense, is proud to announce a new partnership with Signifier® Medical Technologies Ltd, an innovator in the sleep disordered breathing market. This partnership means an expansion of alternative sleep therapy product offerings for First Nation Group’s Federal Government customers and a new connection to a company driving innovation in the sleep market.

“A night of restful sleep is vital, but out of reach for many individuals because either they or their partner suffer from a sleep disorder,” stated Monika Meixelsperger, Business Development Manager at First Nation Group. “First Nation Group is excited to offer Signifier Medical’s eXciteOSA®, the first daytime intraoral neuromuscular stimulation device, to our customers to help those with mild obstructive sleep apnea (OSA).”

“With the First Nation Group partnership, we’re excited to give back to our Veterans — providing them with the first-ever, clinically proven, daytime treatment for sleep disordered breathing,” says Professor Akhil Tripathi, Chief Executive Officer and co-founder of Signifier Medical Technologies.

Signifier Medical, founded in 2015, launched the eXciteOSA daytime therapy device to assist patients who were struggling with conventional treatment options for sleep-disordered breathing. By partnering, First Nation Group and Signifier Medical will bring this FDA-authorized, simple, non-intrusive, and safe product into the government space to help clinicians better serve their patients and, ultimately, aid Veterans in need of a good night’s sleep.

To explore First Nation Group’s newest alternative sleep therapy product offerings, visit us at

And, to learn more about Signifier Medical Technologies and how they’re improving quality of life, sleep, and relationships by tackling the root cause of snoring, visit

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]
2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
4. Clinical study of 115 patients with snoring or mild OSA (Apnea-Hypopnea Index (AHI <15 n=65)). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPAT® night sleep studies before and after the use of the device. An intra-oral tongue stimulator (eXciteOSA®) device was used for 20 mins, once a day for a 6-week period.